In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells
✍ Scribed by Daniel E. Speiser; Danielle Liénard; Mikaël J. Pittet; Pascal Batard; Donata Rimoldi; Philippe Guillaume; Jean-Charles Cerottini; Pedro Romero
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 210 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To assess the ability of rheumatoid arthritis (RA) fibroblast‐like synoviocytes (FLS) to function as antigen‐presenting cells (APCs) for arthritogenic autoantigens found within inflamed joint tissues. ## Methods Human class II major histocompatibility complex (MHC)–typed
Bi-specific antibody fragments (bAB) are used in tumour therapy as a means to redirect and to strengthen effector cell function. It would be of great therapeutic advantage if, in addition, recruitment, expansion and the state of activity of effector cells are influenced by targeting through a bAB. T
## BACKGROUND. Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS. We used a population o
DNA vaccines induce CTL attack on target tumor epitopes, but tumor elimination in vivo also requires sufficient effector CTL to enter the site, guided by inflammatory chemokines. Many herpesviruses contain genes for chemokine and chemokine receptor-like proteins to protect infected cells from immune
Background EBV immortalized B-cells can be used as antigen presenting cells (APC) to stimulate speci®c T-cell responses. Mini-Epstein-Barr virus (mini-EBV) plasmids contain all functional elements of Epstein-Barr virus (EBV) necessary to immortalize B-cells in vitro. These immortalized B-cells are i